Navigation Links
Faulty DNA repair could be a risk factor for lung cancer in nonsmokers
Date:6/26/2008

PHILADELPHIA People who have never smoked but whose cells cannot efficiently repair environmental insults to DNA are at higher risk of developing lung cancer than those with effective genomic repair capability, according to researchers from the Department of Epidemiology at The University of Texas M. D. Anderson Cancer Center.

"About 15 percent of lung cancers occur in lifetime never smokers. Risk factors for lung cancer in people who have never smoked are poorly understood, but this study demonstrates that poor DNA repair capacity is an important predictor of lung cancer risk in never smokers," said the study's lead author, Olga Gorlova, Ph.D., an assistant professor in the Department of Epidemiology.

In the June issue of Cancer Epidemiology, Biomarkers and Prevention, a journal of the American Association for Cancer Research, the researchers say that, overall, nonsmokers with suboptimal DNA repair capacity (DRC) are almost twice as likely to develop lung cancer, compared with nonsmokers with normal DRC. Study participants with the lowest ability to repair their DNA had a more than a threefold increased risk, compared with individuals with efficient DRC.

Secondhand smoke exposure is another established risk factor; in participants with inefficient DRC who also reported such exposure, the risk of lung cancer was almost fourfold.

Although the research team has not pinpointed the gene or genes that cause suboptimal DRC, their data suggest that the trait is heritable to some degree. Notably they found that first-degree relatives of those with lowest DRC were 2.5 times more likely to develop lung cancer than were first-degree relatives of people with efficient DRC.

"Our findings demonstrate that suboptimal DNA repair capacity together with secondhand smoke exposure are strong lung cancer risk factors in lifetime never smokers," Gorlova said.

This is the first study that has looked at functional DNA repair capacity as a risk factor for lung cancer in nonsmokers. Researchers drew white blood cells from 219 lung cancer patients and 309 matched control participants, all of whom had never smoked. They used the cells to conduct a host-cell reactivation assay, a complicated test that introduced a specific carcinogen, benzo[a]pyrene diol epoxide (BPDE) into the cells. BPDE is a hydrocarbon found in smoke of all kinds (tobacco, wood, etc.) that is highly carcinogenic and mutagenic, capable of changing the composition of DNA.

The study is a continuation of research underway at M. D. Anderson that is looking for genetic and epigenetic components to lung cancer risk. The research group has previously shown that DNA repair capacity as measured by the host cell reactivation assay was significantly lower in lung cancer patients who were current or former smokers than in matched controls.

"Many people think they aren't at risk for lung cancer because they don't smoke, but anyone who has non-smoking relatives with lung cancer should avoid not just tobacco smoke, but all the other carcinogens and mutagens that are products of combustion," Gorlova said.


'/>"/>

Contact: Jeremy Moore
Jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Faulty brain connections may be responsible for social impairments in autism
2. St. Jude Finds Mechanism for Faulty Protein Disposal
3. St. Jude finds mechanism for faulty protein disposal
4. Pedophilia may be the result of faulty brain wiring
5. Evalve MitraClip: Clinical trial of nonsurgical repair for severe mitral valve regurgitation
6. 2nd Option Improves Abdominal Aorta Repair Outcomes
7. Joint distraction promotes structural repair in patients with severe knee osteoarthritis
8. Industrial Control Repair Named Honda of America Manufacturings 2007 Supplier of the Year
9. Finding clues for nerve cell repair
10. New stem cell therapy may aid the repair of damaged brains
11. Collaborative Drug Discovery and Myelin Repair Foundation Announce Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: